Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, constitutes a national security threat to the U.S.